Zimmer Biomet reports 4.8% YoY revenue uptick in Q2; raises 2026 outlook

Zimmer Biomet has reported Q2 revenues of astir $2.18bn, denoting a year-over-year (YoY) uptick of 4.8%, and a revised afloat twelvemonth outlook.

Zimmer's knees conception was its strongest performer successful Q2, with income totalling $828.9m, followed by S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) astatine $586m, and hips astatine $562.7m. However, portion Zimmer's exertion and data, bony cement and surgical conception drew successful the lowest profits successful Q2 astatine $199.4m, this conception saw the largest YoY maturation astatine 21.1%, followed by S.E.T. astatine 6.4% and hips astatine 5%. Meanwhile, YoY maturation successful knees remained level astatine 0.4%.

The orthopaedics elephantine present expects 2026 gross maturation to onshore successful the 3.9% to 4.9% range, up from 2.5% to 4.5% previously, with net present mooted to travel successful astatine $8.47-$8.59 per diluted share, up from $8.40-$8.55 previously.

Zimmer released its Q2 financials up of marketplace open. The company's shares connected the New York Stock Exchange (NYSE) roseate by implicit 5% to astir $101.00 astatine marketplace unfastened connected 5 August, up from $95.81 previously. Zimmer Biomet has a marketplace headdress of $19.63bn.

Reflecting connected Zimmer's Q2 performance, Tornos, said: "With a beardown archetypal half, steadfast underlying markets, go-to-market changes progressing arsenic planned and continued momentum from our innovation cycle, we are raising our gross and adjusted net per stock (EPS) guidance for the year.

"Importantly, we proceed to beforehand our strategical priorities and stay assured our efforts volition fortify our business, physique the boldest person successful medtech, and amended presumption Zimmer Biomet to present consistent, durable maturation implicit the agelong term."

Zimmer's revisions to its 2026 outlook travel amid a bid of structural evolutions the institution is undergoing. Upon releasing its 2025 results, Zimmer CEO Ivan Tornos highlighted that the institution antecedently tempered its 2026 outlook fixed its planned concern into a stronger, specialised income unit successful the US, arsenic outlined astatine the J.P. Morgan HealthCare league successful January.

At the time, Tornos besides shared that the grade of occurrence of some planetary marketplace maturation and caller merchandise adoption cycles were further factors successful the company's 2026 forecast.

"Zimmer Biomet reports 4.8% YoY gross uptick successful Q2; raises 2026 outlook" was primitively created and published by Medical Device Network, a GlobalData owned brand.